BiotechTube

Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza Vaccination

Conditions

Influenza Vaccination

Trial Timeline

Sep 29, 2022 → Feb 6, 2024

NCT ID
NCT05479370

About Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine

Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine is a phase 3 stage product being developed by Sanofi for Influenza Vaccination. The current trial status is completed. This product is registered under clinical trial identifier NCT05479370. Target conditions include Influenza Vaccination.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05479370Phase 3Completed

Competing Products

20 competing products in Influenza Vaccination

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
VaccineComac MedicalPhase 3
69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + PlaceboCelltrionPhase 2
52
CT-P27 + PlaceboCelltrionPhase 2
52
CAIV-TPfizerPhase 3
76
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + PlaceboSumitomo PharmaPhase 1
33
Monovalent Influenza VaccineAstraZenecaApproved
85
Monovalent Influenza VaccineAstraZenecaApproved
85
Trivalent Influenza VaccineAstraZenecaApproved
85
AZD4117 + AZD5315AstraZenecaPhase 1/2
41
Trivalent Influenza VaccineAstraZenecaApproved
85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
85
Trivalent Influenza Virus VaccineAstraZenecaApproved
85
Comparator: Modified Process Vaccine + Comparator: COMVAX™MerckPhase 3
77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A VirusMerckPhase 1
33
V512 + Comparator: Placebo to V512MerckPhase 1
33
Vaxelis + PedvaxHIBMerckApproved
85

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84